COVID-19 - BioTuesdays

Developments

iBio featured on ABC affiliate

KXXV, an ABC affiliate in Bryan, Texas, published an article on iBio’s (NYSE AMERICAN:IBIO) two COVID-19 vaccine candidates. The company recently reported that it has selected IBIO-201 as its leading candidate for...

September 11, 2020

Developments

Hepion CRV431 featured on The Bio Report podcast

The Bio Report podcast featured Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431 for the treatment of non-alcoholic steatohepatitis (NASH), and potentially, COVID-19. “We’ve kicked off our Phase 2 trial in NASH...

September 11, 2020

Developments

iBio selects IBIO-201 as its leading COVID-19 vaccine candidate

iBio (NYSE AMERICAN:IBIO) selected IBIO-201 as its leading candidate for the prevention of SARS-CoV-2 infection. iBio previously reported that both of its COVID-19 vaccine candidates, IBIO-200 and IBIO-201, in...

September 9, 2020

Developments

iBio and Planet Biotechnology in pact to develop COVID-19 therapeutic

iBio (NYSE AMERICAN:IBIO) entered into an exclusive worldwide license agreement with Planet Biotechnology for the development of Planet’s COVID-19 therapeutic candidate, ACE2-Fc. ACE2-Fc is a recombinant protein...

August 28, 2020

Developments

Vanda Pharma reports interim results from Phase 3 COVID-19 trial

Vanda Pharmaceuticals (NASDAQ:VNDA) reported interim results from its Phase 3 trial assessing tradipitant for the treatment of COVID-19 pneumonia. The data are based on the first 60 patients enrolled in the study, who...

August 18, 2020

Developments

Omeros reports positive results from COVID-19-associated ARDS trial

Omeros (NASDAQ:OMER) reported positive results from a study evaluating narsoplimab for the treatment of COVID-19-associated acute respiratory distress syndrome (ARDS). Narsoplimab is a human monoclonal antibody that is...

August 10, 2020

Developments

IBIO-201 demonstrates ability to elicit anti-SARS-CoV-2 immune response in preclinical studies

iBio (NYSE AMERICAN:IBIO) reported initial results from preclinical studies of IBIO-201, one of its two COVID-19 vaccine candidates. IBIO-201 is a subunit vaccine that combines antigens derived from the SARS-CoV-2 spike...

August 10, 2020

Developments

The Hill’s coronavirus report features iBio COVID-19 vaccine candidates and FastPharming System

iBio’s (NYSE AMERICAN:IBIO) two COVID-19 vaccine candidates and FastPharming manufacturing system were featured on The Hill’s coronavirus report on July 30. The company is developing IBIO-200 and IBIO-201, virus-like...

July 30, 2020

Developments

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

The first patients have been enrolled in an investigator-sponsored Phase 2 study evaluating Immunic Therapeutics‘ (NASDAQ:IMUX) IMU-838 for the treatment of COVID-19. IMU-838 is a selective immune modulator that...

July 27, 2020

Developments

Cerecor enrolls first patient in COVID-19 trial

Cerecor (NASDAQ:CERC) enrolled the first patient in its a proof-of-concept trial evaluating CERC-002 in patients with COVID-19 cytokine storm-induced acute respiratory distress syndrome (ARDS). CERC-002 is a...

July 21, 2020

Developments

PhaseBio doses first COVID-19 patient in Phase 2 trial

PhaseBio Pharmaceuticals (NASDAQ:PHAS) dosed the first patient in its potentially pivotal Phase 2 trial evaluating PB1046 for the treatment of high-risk, hospitalized COVID-19 patients. PB1046 is a long-acting analog of...

July 17, 2020

Markets

HCW ups electroCore PT to $2.50 from $1.50

H.C. Wainwright raised its price target for electroCore (NASDAQ:ECOR) to $2.50 from $1.50, citing the FDA’s emergency use authorization of gammaCore, the company’s lead product, to treat COVID-19 patients. The stock...

July 15, 2020

Developments

Rigel Pharma fostamatinib being evaluated in COVID-19 pneumonia trial

Rigel Pharmaceuticals’ (NASDAQ:RIGL) fostamatinib is being evaluated in an investigator-sponsored study for the treatment of COVID-19 pneumonia. Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, is approved...

July 14, 2020

Developments

Akebia vadadustat being evaluated for COVID-19-related acute respiratory distress syndrome

Akebia Therapeutics’ (NASDAQ:AKBA) vadadustat is being evaluated in an investigator-sponsored study as a potential therapy to prevent and lessen the severity of COVID-19-related acute respiratory distress syndrome...

July 14, 2020

Developments

BioSig subsidiary begins enrollment in Phase 2 COVID-19 trial

ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies (NASDAQ: BSGM), began enrolling patients in its Phase 2 clinical trial of merimepodib for the treatment of COVID-19. Merimepodib is an orally...

July 13, 2020

Developments

Bellerophon treats first COVID-19 patient in Phase 3 INOpulse study

Bellerophon Therapeutics (NASDAQ:BLPH) treated the first patient in its Phase 3 study evaluating INOpulse, a pulsed nitric oxide system, for the treatment of COVID-19. The study will enroll up to 500 patients requiring...

July 13, 2020

Developments

FDA authorizes emergency use of electroCore’s vagus nerve stimulation in COVID-19 patients

The FDA has issued an emergency use authorization for electroCore’s (NASDAQ:ECOR) gammaCore Sapphire CV non-invasive vagus nerve stimulation (nVNS) to treat adult patients with known or suspected COVID-19. The FDA has...

July 13, 2020

Developments

Hepion Pharma posts preclinical data supporting two-pronged approach treating COVID-19 with CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that its anti-fibrotic drug candidate, CRV431, was efficacious in two distinct preclinical research models related to COVID-19 disease. CRV431 demonstrated strong anti...

July 7, 2020

Developments

Luminal BioSciences provides guidance on milestones; begins collecting plasma from COVID-19 recovered donors

Liminal BioSciences (NASDAQ, TSX:LMNL) provided a guidance update on the timing of certain expected key milestones for 2020. The company withdrew guidance in May because of the COVID-19 pandemic. In a statement, Kenneth...

July 1, 2020

Developments

Texas A&M video series features iBio COVID-19 vaccines

iBio’s (NYSE American:IBIO) two COVID-19 vaccine candidates were featured on the final episode of the video series, “COVID-19: The Texas A&M University System Responds.” “This is an important collaboration,” John...

June 26, 2020

Developments

Kamada IgG therapy cleared for compassionate COVID-19 use in Israel

Kamada (NASDAQ, TASE:KMDA) completed manufacturing of the first batch of its plasma-derived immunoglobulin (IgG) product for the treatment of COVID-19 and the initial vials are available for compassionate use in Israel...

June 17, 2020

Developments

PharmAust lab tests show positive signs for suppressing COVID-19

PharmAust (ASX:PAA) posted positive preliminary results in experiments aimed at inhibiting the virus that causes COVID-19. PharmAust, which traditionally is focused on repurposing existing drugs for cancer therapy, is...

June 4, 2020

iBio featured on ABC affiliate

Hepion CRV431 featured on The Bio Report podcast

iBio selects IBIO-201 as its leading COVID-19 vaccine candidate

iBio and Planet Biotechnology in pact to develop COVID-19 therapeutic

Vanda Pharma reports interim results from Phase 3 COVID-19 trial

Omeros reports positive results from COVID-19-associated ARDS trial

IBIO-201 demonstrates ability to elicit anti-SARS-CoV-2 immune response in preclinical studies

The Hill’s coronavirus report features iBio COVID-19 vaccine candidates and FastPharming System

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

Cerecor enrolls first patient in COVID-19 trial

PhaseBio doses first COVID-19 patient in Phase 2 trial

HCW ups electroCore PT to $2.50 from $1.50

Rigel Pharma fostamatinib being evaluated in COVID-19 pneumonia trial

Akebia vadadustat being evaluated for COVID-19-related acute respiratory distress syndrome

BioSig subsidiary begins enrollment in Phase 2 COVID-19 trial

Bellerophon treats first COVID-19 patient in Phase 3 INOpulse study

FDA authorizes emergency use of electroCore’s vagus nerve stimulation in COVID-19 patients

Hepion Pharma posts preclinical data supporting two-pronged approach treating COVID-19 with CRV431

Luminal BioSciences provides guidance on milestones; begins collecting plasma from COVID-19 recovered donors

Texas A&M video series features iBio COVID-19 vaccines

Kamada IgG therapy cleared for compassionate COVID-19 use in Israel

PharmAust lab tests show positive signs for suppressing COVID-19

General

More